Top Page
Haleon PLC
(LSE:HLN)
Haleon PLC (HLN) vs. iShares MSCI United Kingdom ETF (EWC)
Haleon PLC Business Overview & Revenue Model
Haleon PLC Earnings Call Summary
Haleon PLC Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 11.26B | 11.23B | 11.30B | 10.86B | 9.54B | 9.89B | Gross Profit |
| 6.83B | 6.82B | 6.75B | 6.58B | 5.95B | 5.91B | EBIT |
| 2.01B | 2.21B | 2.00B | 1.82B | 1.64B | 1.60B | EBITDA |
| 2.11B | 2.63B | 2.36B | 2.19B | 2.21B | 1.92B | Net Income Common Stockholders |
| 1.09B | 1.44B | 1.05B | 1.06B | 1.39B | 1.15B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 1.04B | 2.19B | 1.04B | 684.00M | 414.00M | 334.00M | Total Assets |
| 0.00 | 34.31B | 34.05B | 34.81B | 34.45B | 34.13B | Total Debt |
| 0.00 | 10.10B | 9.46B | 10.44B | 991.00M | 487.00M | Net Debt |
| 1.04B | 7.91B | 8.41B | 9.76B | 577.00M | 153.00M | Total Liabilities |
| 0.00 | 18.09B | 17.33B | 18.36B | 7.97B | 7.91B | Stockholders Equity |
| 16.73B | 16.17B | 16.61B | 16.33B | 26.36B | 26.11B |
| Cash Flow | Free Cash Flow | ||||
| 0.00 | 1.98B | 1.76B | 1.74B | 1.06B | 1.09B | Operating Cash Flow |
| 0.00 | 2.30B | 2.10B | 2.06B | 1.36B | 1.41B | Investing Cash Flow |
| 0.00 | 528.00M | -134.00M | -8.78B | -33.00M | 1.03B | Financing Cash Flow |
| 0.00 | -1.54B | -1.57B | 6.91B | -1.24B | -2.44B |
Haleon PLC Technical Analysis
Haleon PLC Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | £206.28M | 5.71 | 33.70% | 1.67% | -0.17% | 2591.96% | |
71 Outperform | £4.63B | 16.58 | 15.79% | 2.95% | 5.83% | 83.35% | |
70 Outperform | £35.91B | 25.54 | 8.80% | 1.65% | -0.61% | 39.00% | |
54 Neutral | $5.28B | 3.29 | -45.38% | 2.80% | 16.77% | -0.08% | |
51 Neutral | £324.12M | ― | -369.20% | ― | 4.50% | 74.32% |
Haleon PLC Corporate Events
Haleon PLC has announced the purchase and cancellation of 815,673 ordinary shares as part of its share buyback programme initiated in March 2025. This transaction impacts the company’s share capital, reducing the number of shares with voting rights, which may influence shareholder notifications under regulatory guidelines.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the purchase and cancellation of 794,956 ordinary shares as part of its ongoing share buyback program. This move is part of a strategic effort to manage its capital structure, potentially enhancing shareholder value and reflecting confidence in the company’s financial health. The transaction adjusts the company’s share capital, affecting the number of shares with voting rights, which stakeholders should note for regulatory compliance.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced a notification regarding the shareholding of Ed Petter, Chief Corporate Affairs Officer, who received the first tranche of Haleon Ordinary Shares under the company’s Share Value Plan. This award was part of his remuneration package to compensate for incentives forfeited from his previous employment, and it is subject to malus and clawback provisions. This transaction reflects Haleon’s adherence to UK Market Abuse Regulations and highlights the company’s commitment to transparent executive compensation practices.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the purchase of 794,623 ordinary shares for cancellation as part of its share buyback program initiated in March 2025. This transaction reflects Haleon’s strategic focus on optimizing its capital structure and potentially enhancing shareholder value by reducing the number of shares with voting rights, which now stands at 9,000,455,357.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced that as of May 31, 2025, it has issued a total of 9,005,330,185 ordinary shares, with 4,080,205 held as treasury shares. This results in 9,001,249,980 shares having voting rights, a figure crucial for shareholders and others with notification obligations under the FCA’s Disclosure Guidance and Transparency Rules. This update is significant for stakeholders as it impacts the calculation of their interests in the company.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the purchase of 797,519 ordinary shares as part of its share buyback program, initially announced in March 2025. This transaction reflects the company’s strategic financial management, potentially enhancing shareholder value and consolidating its market position by reducing the number of shares with voting rights to 9,001,249,980.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the purchase of 802,236 ordinary shares as part of its share buyback program, initially announced in March 2025. This transaction, aimed at optimizing the company’s capital structure, reduces the number of shares with voting rights to 9,005,256,948, potentially impacting shareholder interests and market positioning.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the purchase and cancellation of 810,332 ordinary shares as part of its share buyback program, initially announced in March 2025. This transaction is part of Haleon’s strategy to manage its share capital and potentially enhance shareholder value, reflecting its commitment to maintaining a strong market position.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the purchase and cancellation of 816,897 ordinary shares as part of its share buyback program, which was initiated on March 28, 2025. This transaction is part of a strategic move to optimize the company’s capital structure, potentially enhancing shareholder value and reflecting confidence in its long-term growth prospects.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the purchase of 820,774 ordinary shares as part of its share buyback program, which was initially announced on March 28, 2025. This transaction is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value. Following this purchase, Haleon’s registered share capital consists of over 9 billion ordinary shares, with a significant portion held as treasury shares, impacting the number of shares with voting rights.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced a notification regarding a transaction by a person discharging managerial responsibilities. Bláthnaid Bergin, an Independent Non-Executive Director, purchased 6,145 ordinary shares at £4.0427 each on 16 May 2025, as per the UK Market Abuse Regulation disclosure requirements. This transaction could indicate confidence in the company’s future performance and may impact stakeholder perceptions positively.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC has announced the purchase of 825,666 ordinary shares for cancellation as part of its share buyback program initiated in March 2025. This transaction reflects the company’s strategic move to optimize its capital structure, potentially enhancing shareholder value and maintaining a robust market position. The updated share capital now stands at 9,012,587,392 ordinary shares, with 9,008,507,187 shares possessing voting rights.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the purchase and cancellation of 840,928 ordinary shares as part of its share buyback programme. This move is part of a strategic effort to manage its capital structure and potentially enhance shareholder value. Following this transaction, Haleon’s registered share capital consists of over 9 billion ordinary shares, with a significant portion held as treasury shares. This adjustment in share capital may influence shareholder voting rights and interests under regulatory guidelines.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the purchase of 835,518 of its own ordinary shares as part of its share buyback program, which was initially announced in March 2025. This transaction reduces the number of shares with voting rights to 9,010,173,781, potentially impacting shareholder interests and market dynamics.
The most recent analyst rating on (GB:HLN) stock is a Buy with a £4.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC has announced the purchase and cancellation of 820,380 ordinary shares as part of its ongoing share buyback program. This move is aimed at optimizing its capital structure, potentially enhancing shareholder value by reducing the number of shares with voting rights to 9,011,009,299. The transaction reflects Haleon’s strategic financial management and commitment to maintaining a robust market position.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the acquisition of Partnership Shares and the award of Matching Shares under its Share Reward Plan by two of its senior executives, Adrian Morris and Tamara Rogers. This notification, in compliance with the UK Market Abuse Regulation, highlights the company’s commitment to aligning managerial interests with shareholder value, potentially strengthening its market position and stakeholder confidence.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced a transaction involving Marie-Anne Aymerich, an Independent Non-Executive Director, who purchased 21,300 ordinary shares at £4.051 each on the London Stock Exchange. This transaction highlights the confidence of the company’s leadership in Haleon’s market position and future prospects, potentially impacting stakeholder perceptions positively.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the purchase of 814,534 ordinary shares for cancellation as part of its share buyback program. This move is part of the company’s strategy to manage its share capital and potentially enhance shareholder value, impacting the number of shares with voting rights and aligning with regulatory requirements.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the purchase and cancellation of 830,397 ordinary shares as part of its ongoing share buyback programme. This move is part of the company’s strategy to manage its share capital and potentially enhance shareholder value by reducing the number of shares in circulation, which may impact voting rights and shareholding notifications under regulatory guidelines.
Haleon PLC announced the purchase and cancellation of 830,504 ordinary shares as part of its share buyback program initiated in March 2025. This transaction adjusts the company’s registered share capital and the number of shares with voting rights, impacting shareholder notifications under regulatory guidelines.
Haleon PLC announced the purchase and cancellation of 828,853 ordinary shares as part of its ongoing share buyback program. This transaction reflects the company’s strategic financial management, potentially enhancing shareholder value and adjusting its capital structure. The update on the company’s share capital and voting rights is crucial for stakeholders to assess their interests in accordance with regulatory requirements.
Haleon PLC has announced the publication of listing particulars for its £10 billion Euro Medium Term Note Programme, which is guaranteed by the company. This routine update is significant as it underscores Haleon’s commitment to maintaining transparency and accessibility for its investors, potentially impacting its financial strategy and market perception.
Haleon PLC announced the purchase and cancellation of 832,200 ordinary shares as part of its share buyback program. This move is part of a strategic effort to manage its share capital and potentially enhance shareholder value by reducing the number of shares in circulation, thereby increasing the value of remaining shares.
Haleon PLC announced the repurchase of 85,611 of its ordinary shares as part of its share buyback program, initially announced in March 2025. This transaction reflects the company’s strategic effort to manage its capital structure and enhance shareholder value, with implications for voting rights and shareholder notifications under regulatory guidelines.
Haleon PLC announced the repurchase of 846,782 ordinary shares as part of its share buyback program, initially announced in March 2025. This transaction is intended to optimize the company’s capital structure and enhance shareholder value. Following this purchase, Haleon’s registered share capital consists of 9,026,151,961 ordinary shares, with 9,022,071,756 shares carrying voting rights. This strategic move is expected to strengthen Haleon’s market position and potentially impact stakeholder interests by adjusting the company’s shareholding structure.
Haleon PLC announced the purchase and cancellation of 846,648 ordinary shares as part of its share buyback program initiated in March 2025. This transaction adjusts the company’s share capital and affects the number of shares with voting rights, which stakeholders can use to assess their interests under regulatory guidelines.
Haleon PLC announced the purchase of 855,279 ordinary shares for cancellation as part of its share buyback program. This transaction, which was executed at a volume-weighted average price of 379.18 pence per share, is part of a strategic move to optimize the company’s capital structure and potentially enhance shareholder value. Following this transaction, the company’s registered share capital stands at 9,028,701,792 ordinary shares, with 9,024,621,587 shares holding voting rights, which may impact shareholder notifications under regulatory guidelines.
Haleon PLC has announced its agreement to acquire the remaining 12% equity interest in its Chinese joint venture, Tianjin TSKF Pharmaceutical Co., Ltd., making it a wholly owned subsidiary. This acquisition, valued at approximately £0.2 billion, is expected to be funded through existing cash resources and new Renminbi-denominated debt, with the transaction anticipated to close within three months, pending customary approvals.
Haleon PLC announced the purchase of 865,652 ordinary shares as part of its share buyback program, which was initiated on March 28, 2025. This transaction is part of Haleon’s strategy to manage its capital structure and enhance shareholder value, reflecting confidence in the company’s financial health and future prospects.
Haleon PLC announced the purchase of 887,346 ordinary shares for cancellation as part of its share buyback programme, impacting its share capital and voting rights. This move is part of Haleon’s strategy to manage its capital structure and could influence shareholder decisions under regulatory guidelines.
Haleon PLC announced the purchase of 821,144 ordinary shares for cancellation as part of its share buyback program. This transaction is part of Haleon’s strategy to manage its share capital and potentially enhance shareholder value. The company’s registered share capital now stands at 9,034,845,270 ordinary shares, with 9,030,765,065 shares having voting rights. This move reflects Haleon’s ongoing efforts to optimize its financial structure and could have implications for its market positioning and shareholder engagement.
Haleon PLC announced the purchase of 826,862 ordinary shares for cancellation as part of its share buyback programme initiated on 28 March 2025. This transaction impacts the company’s share capital, reducing the number of ordinary shares with voting rights to 9,032,421,345, which stakeholders can use to assess their interests under the FCA’s Disclosure Guidance and Transparency Rules.
Haleon PLC announced the purchase of 828,379 ordinary shares for cancellation as part of its share buyback program. This transaction affects the company’s share capital, reducing the number of ordinary shares with voting rights to 9,033,248,207. The buyback program is part of Haleon’s strategy to manage its capital structure and potentially enhance shareholder value.
Haleon PLC announced that as of March 31, 2025, the total number of shares issued is 9,038,156,791, with 4,080,205 held as treasury shares. The number of ordinary shares with voting rights is 9,034,076,586, which shareholders should use as the denominator for determining notification obligations under the FCA’s Disclosure Guidance and Transparency Rules.
Haleon PLC announced the purchase and cancellation of 831,399 ordinary shares as part of its share buyback programme. This transaction is part of their strategy to manage their share capital and potentially enhance shareholder value. The buyback reduces the number of shares with voting rights to 9,034,076,586, which may impact shareholder notifications under the FCA’s Disclosure Guidance and Transparency Rules.
Haleon PLC announced the repurchase of 581,885 ordinary shares as part of its share buyback program, initially announced on March 28, 2025. This transaction is part of Haleon’s strategy to manage its share capital and enhance shareholder value, impacting the number of shares with voting rights, which now stands at 9,034,907,985.
Haleon PLC has announced the purchase and cancellation of 581,885 ordinary shares as part of its share buyback programme. This move is expected to impact the company’s share capital and voting rights, with the number of ordinary shares with voting rights now standing at 9,034,907,985. The buyback is part of Haleon’s strategy to manage its capital structure and enhance shareholder value.
Haleon PLC has announced the commencement of a share buyback programme, aiming to purchase up to £330 million worth of ordinary shares in 2025. This initiative follows a previous off-market purchase from Pfizer Inc. and aligns with Haleon’s capital allocation priorities to enhance shareholder returns. The first tranche of this programme, valued at up to £200 million, will begin immediately and conclude by June 2025, with Goldman Sachs International managing the purchases on the London Stock Exchange. This buyback is expected to reduce the company’s share capital and improve earnings per share, reflecting Haleon’s strategic focus on delivering value to its shareholders.
Haleon PLC announced that Pfizer Inc. has sold its entire residual interest in the company, amounting to 661,709,764 ordinary shares. This transaction, which included a secondary offering and an off-market sale, marks Pfizer’s complete exit from its stake in Haleon, potentially impacting the company’s shareholder structure and market dynamics.
Haleon PLC announced the issuance of share awards to its key executives under various performance and bonus plans. These awards, which are part of the company’s remuneration policy, are designed to incentivize and retain top management by aligning their interests with company performance. The move underscores Haleon’s commitment to maintaining strong leadership and could have implications for its market positioning by ensuring continued strategic focus and operational excellence.
Haleon PLC has completed an off-market purchase of 44,155,844 ordinary shares from Pfizer Inc. for approximately £170 million, subsequently canceling these shares. This transaction affects the total voting rights and capital structure, with the number of ordinary shares with voting rights now standing at 9,035,489,870. This adjustment is significant for shareholders and others with notification obligations under the FCA’s Disclosure Guidance and Transparency Rules.
Haleon PLC has released its Annual Report and Form 20-F for the year ending December 31, 2024. The report is available on the company’s website and has been submitted to both the National Storage Mechanism and the US Securities and Exchange Commission. Shareholders can request a hard copy of the report, which includes the company’s complete audited financial statements. The Annual General Meeting is scheduled for May 28, 2025, with further details to be distributed to shareholders.
Haleon PLC announced a change in its major holdings, with Wellington Management Group LLP increasing its voting rights from 5.1% to 5.87%. This adjustment in holdings reflects Wellington’s strategic positioning and potential influence within Haleon, indicating a strengthened relationship that could impact the company’s future governance and strategic decisions.
Haleon PLC has agreed to purchase 44,155,844 ordinary shares from Pfizer Inc. as part of an off-market transaction, marking Pfizer’s complete exit from its stake in Haleon. This move aligns with Haleon’s capital allocation priorities and strengthens its position to capitalize on future opportunities, as the company continues to focus on delivering attractive returns for shareholders.
Haleon PLC has announced an agreement with Pfizer Inc. to purchase approximately £170 million worth of its own ordinary shares from Pfizer, contingent upon the completion of Pfizer’s proposed offering to institutional investors. This off-market purchase is part of Haleon’s £500 million share buyback plan for 2025, and the company intends to cancel the acquired shares, potentially impacting its market positioning and shareholder value.
Haleon PLC announced the vesting of share awards under its Performance Share Plan 2022 and Share Value Plan 2022, which were granted to key managerial personnel. These awards, which include dividends and are contingent on continued employment and performance conditions, were partially sold to cover tax liabilities. The disclosure aligns with UK Market Abuse Regulation requirements, highlighting Haleon’s commitment to transparency and regulatory compliance.
Haleon PLC announced the acquisition of partnership shares and the award of matching shares to key managerial personnel under the company’s Share Reward Plan. This move, disclosed in compliance with the UK Market Abuse Regulation, involves transactions by Adrian Morris, General Counsel, and Tamara Rogers, Chief Marketing Officer. The transactions, conducted on the London Stock Exchange, reflect Haleon’s commitment to aligning managerial interests with company performance, potentially enhancing stakeholder confidence and reinforcing its market position.